NCT02354274 Novel Approach to Radiotherapy in Locally Advanced Lung Cancer Concomitant Navelbine®
| NCT ID | NCT02354274 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Olfred Hansen |
| Condition | NSCLC |
| Study Type | INTERVENTIONAL |
| Enrollment | 330 participants |
| Start Date | 2015-01 |
| Primary Completion | 2029-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 330 participants in total. It began in 2015-01 with a primary completion date of 2029-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To investigate the effect of escalation of radiation dose to tumor and lymph nodes based on an inhomogeneous dose distribution controlled by FDG-PET positive areas compared to a standard homogeneous dose spread
Eligibility Criteria
Inclusion Criteria: * Patients with histologically or cytologically proven locally advanced NSCLC stage IIB to IIIB * Performance status 0-1 * Able to comply with treatment and follow study and follow-up procedures * Women must have negative pregnancy test * Signed, informed consent * Plan for radiotherapy with conventional 66 Gy/ 33 F, which meets all dosing limits two normal tissue must be available Exclusion Criteria: * Any unstable systemic disorder (including infection , unstable angina, congestive heart failure , severe liver , kidney or metabolic disease) * Need for nasal oxygen * Former thoracic radiotherapy, unless there is no significant overlap with previous fields * Any other active malignant disease * Unable to take oral medications or needing intravenous nutrition * Ulcer * Nursing women
Contact & Investigator
Frequently Asked Questions
Who can join the NCT02354274 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying NSCLC. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02354274 currently recruiting?
Yes, NCT02354274 is actively recruiting participants. Contact the research team at olfred.hansen@rsyd.dk for enrollment information.
Where is the NCT02354274 trial being conducted?
This trial is being conducted at Aalborg, Denmark, Aarhus, Denmark, Copenhagen, Denmark, Herlev, Denmark and 3 additional locations.
Who is sponsoring the NCT02354274 clinical trial?
NCT02354274 is sponsored by Olfred Hansen. The trial plans to enroll 330 participants.